Oppenheimer analyst Jeff Jones lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $20 from $21 and keeps an Outperform rating on the shares. The firm notes Y-mAbs Therapeutics reported Q1 results, including $20.9M in Danyelza revenue beating OPCO/consensus estimates of $19.5/19.6M respectively. Management maintained 2025 full-year revenue guidance at $75-90M, with Q2 guidance of $17M-$19M, below Q1 2025. Oppenheimer’s main concern with Q1 revenue is the sequential quarter-over-quarter $3.5M decrease in revenue from the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Positive Outlook for Y-Mabs Therapeutics Amid Strategic Developments and NCCN Inclusion
- Y-mAbs Therapeutics Reports Q1 2025 Financial Results
- Cautious Outlook on Y-Mabs Therapeutics Amidst Competitive and Enrollment Challenges
- UnitedHealth suspends outlook, Under Armour reports Q4 beat; Morning Buzz
- Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension